Astrazeneca (AZN) Common Equity (2009 - 2026)

Astrazeneca's Common Equity history runs 18 years deep, the most recent figure standing at $47.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 15.2% year-over-year to $47.4 billion; the TTM figure through Mar 2026 stood at $47.4 billion (up 15.2% YoY), while the FY2025 annual figure was $48.7 billion, up 19.45% from the prior year.
• Common Equity was $47.4 billion for Q1 2026 at Astrazeneca, down from $48.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $48.7 billion in Q4 2025 to a low of $35.2 billion in Q3 2022.
• Historically, Common Equity has averaged $40.0 billion across 5 years, with a median of $39.2 billion in 2023.
• Biggest YoY gain for Common Equity was 218.55% in 2022; the steepest drop was 11.92% in 2022.
• A 5-year view of Common Equity shows it stood at $37.1 billion in 2022, then increased by 5.69% to $39.2 billion in 2023, then increased by 4.14% to $40.8 billion in 2024, then advanced by 19.45% to $48.7 billion in 2025, then fell by 2.74% to $47.4 billion in 2026.
• The last three Common Equity figures came in at $47.4 billion (Q1 2026), $48.7 billion (Q4 2025), and $46.0 billion (Q3 2025), per Business Quant data.